ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Texas Permanent School Fund

Texas Permanent School Fund cut its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Rating) by 7.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,683 shares of the specialty pharmaceutical company’s stock after selling 688 shares during the quarter. Texas Permanent School Fund’s holdings in ANI Pharmaceuticals were worth $279,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Swiss National Bank grew its position in shares of ANI Pharmaceuticals by 9.6% in the second quarter. Swiss National Bank now owns 29,600 shares of the specialty pharmaceutical company’s stock valued at $878,000 after purchasing an additional 2,600 shares during the last quarter. Public Sector Pension Investment Board grew its position in shares of ANI Pharmaceuticals by 2.1% in the second quarter. Public Sector Pension Investment Board now owns 24,249 shares of the specialty pharmaceutical company’s stock valued at $719,000 after purchasing an additional 499 shares during the last quarter. Jackson Creek Investment Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $1,120,000. Thompson Siegel & Walmsley LLC grew its position in shares of ANI Pharmaceuticals by 2.8% in the second quarter. Thompson Siegel & Walmsley LLC now owns 435,873 shares of the specialty pharmaceutical company’s stock valued at $12,932,000 after purchasing an additional 11,786 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at approximately $204,000. 67.89% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ ANIP opened at $43.95 on Tuesday. ANI Pharmaceuticals, Inc. has a 1 year low of $22.31 and a 1 year high of $44.86. The firm’s 50 day moving average price is $39.66 and its 200 day moving average price is $36.37. The firm has a market cap of $767.59 million, a P/E ratio of -9.81 and a beta of 1.03. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.62 and a current ratio of 3.79.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Rating) last announced its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.06. The firm had revenue of $83.82 million for the quarter, compared to analyst estimates of $78.71 million. ANI Pharmaceuticals had a negative net margin of 23.95% and a positive return on equity of 2.65%. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 0.66 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, October 12th. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $49.00.

About ANI Pharmaceuticals

(Get Rating)

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.